Abstract

Results Before challenge, all animals raised SIV-specific T-cells as evidenced by IFN-γ ELISPOT (110 ± 42, 921 ± 310 and 905 ± 252 spots/106 cells in the ID only, ID+EP and ID+EP+genetic-adjuvant groups, respectively). Weak and transient antibody responses were detected. All animals were intrarectally challenged with pathogenic SIVmac251. T-cell responses increased in both ID+EP groups as early as week 1 post-challenge (3,898 ± 395 and 3,031 ± 893 spots, respectively), and up to 12,000 spots by week 2. Macaques immunized ID only raised delayed and lower responses remaining earlier and higher than in controls. At peak of viremia, plasma viral load was significantly reduced (p = 0.0104) in the ID+EP group. Interestingly, no reduction of plasma viral load was observed by that time in the genetic-adjuvant group despite high anamnestic responses. Differences in anti-Gag responses may explain this observation. Viremia was not reduced in the ID only group. At set-point, although similar plasma viral load in all groups, reduction of SIV-DNA copies in rectal biopsies was observed in the vaccinated animals.

Highlights

  • We recently demonstrated that intradermal (ID) injection with electropororation (EP) of a new HIV DNA vaccine induced strong and persistent specific T-cells in macaques

  • Eighteen macaques were vaccinated with 1 mg of the auxo-GTU-MultiSIV DNA at week 0, 4 and 12: either by the ID route only (n = 6), or by the ID route combined with EP (ID+EP; n = 6) or ID+EP with co-injection of a plasmid used as ''genetic-adjuvant'' (n = 6)

  • No reduction of plasma viral load was observed by that time in the genetic-adjuvant group despite high anamnestic responses

Read more

Summary

Open Access

Efficacy study of a T-cell-based DNA vaccine delivered by intradermal electrotransfer in macaques. Address: 1FIT Biotech, Tartu, Estonia, 2FIT Biotech Oyj Plc, Tampere, Finland, 3Institute of Technology, University of Tartu, Tartu, Estonia and 4Institute for Emerging Diseases and Innovative Therapies, DSV, CEA/Division of Immuno-Virology, Fontenay aux Roses, France. Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):O33 doi:10.1186/1742-4690-6-S3-O33. AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf

Background
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call